A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy
about
Immunometabolism of regulatory T cellsAdjunct Strategies for Tuberculosis Vaccines: Modulating Key Immune Cell Regulatory Mechanisms to Potentiate VaccinationAdvances in Cancer Immunotherapy in Solid TumorsImmune checkpoint blockade for hematologic malignancies: a reviewApplying Precision Medicine and Immunotherapy Advances from Oncology to Host-Directed Therapies for Infectious DiseasesActivation of the A2B adenosine receptor in B16 melanomas induces CXCL12 expression in FAP-positive tumor stromal cells, enhancing tumor progression.Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacyMedicinal chemistry of adenosine, P2Y and P2X receptors.A network based approach to drug repositioning identifies plausible candidates for breast cancer and prostate cancer.CD73: A potential biomarker for anti-PD-1 therapyPreparation and characterization of a novel nanobody against T-cell immunoglobulin and mucin-3 (TIM-3).Targeting CD73 in the tumor microenvironment with MEDI9447.Prognostic impact of CD73 and A2A adenosine receptor expression in non-small-cell lung cancer.Interleukin-2, Ipilimumab, and Anti-PD-1: Clinical Management and the Evolving Role of Immunotherapy for the Treatment of Patients With Metastatic Melanoma.Cancer Immunotherapy: Selected Targets and Small-Molecule Modulators.Potential Therapeutic Applications of Adenosine A2A Receptor Ligands and Opportunities for A2A Receptor Imaging.Adenosine-mediated immunosuppression in patients with squamous cell carcinoma of the head and neck.Safety issues of compounds acting on adenosinergic signalling.The role of 5-arylalkylamino- and 5-piperazino- moieties on the 7-aminopyrazolo[4,3-d]pyrimidine core in affecting adenosine A1 and A2A receptor affinity and selectivity profiles.Metabolites: deciphering the molecular language between DCs and their environment.Targeting neoantigens to augment antitumour immunity.The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets.Targeting adenosine in cancer immunotherapy: a review of recent progress.Metabolic Cooperation and Competition in the Tumor Microenvironment: Implications for Therapy.The interplay between metabolic remodeling and immune regulation in glioblastoma.Role of extracellular cysteine residues in the adenosine A2A receptor.Inhibition of Wnt/β-Catenin pathway and Histone acetyltransferase activity by Rimonabant: a therapeutic target for colon cancer.A covalent antagonist for the human adenosine A2A receptor.2-Amino[1,2,4]triazolo[1,5-c]quinazolines and Derived Novel Heterocycles: Syntheses and Structure-Activity Relationships of Potent Adenosine Receptor Antagonists.Structural Connection between Activation Microswitch and Allosteric Sodium Site in GPCR Signaling.Next generation of immune checkpoint therapy in cancer: new developments and challenges.When worlds collide: Th17 and Treg cells in cancer and autoimmunity.Cryo-EM structure of the adenosine A2A receptor coupled to an engineered heterotrimeric G protein.Immune Checkpoint Inhibitors to Treat Malignant Lymphomas.The human lymph node microenvironment unilaterally regulates T-cell activation and differentiation
P2860
Q28074509-521F7D76-00FD-4709-92ED-40F3F11128E1Q28074536-7DDE710A-09A7-468A-A24C-93446A689D81Q28080113-D793F679-693A-4249-8D65-AFAEAB1EA4B5Q33645590-776AAA6D-DCCD-4229-AE8B-5C555E70892EQ33849778-22285384-3F57-416F-835B-A76F1BEE991CQ34539323-64CD4A59-3DB3-40B1-9838-60EDEC24136CQ34550649-22696B08-55E2-4493-9A47-643B486D169AQ35873582-DAB0D64B-23D1-4263-B6D7-A068C4334E27Q36090771-F1A43D7E-9895-471E-81D2-745E57BD42A9Q36107945-EE5BD843-34B4-4CFC-AD92-E30A45275E85Q36213059-0934D547-4466-441E-A0D7-C2D3A5EC3C24Q37224639-CF2B6E41-95B5-4A06-BEBB-8488D33C440FQ37702792-AFEBE05E-C77A-417C-9FA6-FE1A09B725C0Q38595251-099047EE-CC26-4660-81F9-95BCD70AD519Q38719858-908C695C-8437-40FA-ACA7-F8566C0A0E90Q38765118-32D865AE-2874-4476-AA34-6EAC70083791Q38800033-54BE3A0A-4245-4E00-B7BC-890650396D11Q38843185-8EBFAA2D-30E5-4111-B762-785AEA9A5C02Q39003888-ABDEE671-942F-41CA-A47F-A68A0E3FE2BBQ39030292-1F24B13D-D77A-4BC0-9653-16ED544B96F3Q39149196-D8DD05D9-BA77-4DAD-8D6D-A86374F28CCAQ39161005-AAD7B40D-936F-4062-A8F1-838652A39B1FQ39235260-66702B00-1865-4A11-A50D-1DED08A05FF3Q39265746-D5306DAA-1C14-498A-B735-DA57181241A7Q39328710-6B75D446-8EBE-4083-B3E6-5979C283AA6BQ40932261-51F918AD-4A51-4DE9-A458-EE9701E9C1E1Q41718159-8E8567FD-5F90-4F35-821A-62377459363CQ41763691-D7D553E0-4730-4339-A558-D3B9F07680FAQ46475985-2B654CA2-5807-4E85-9AA7-5979F3CABF71Q50207906-FF6837C8-A7CC-45F4-89F1-7A9C8E3FE4EEQ52653710-29D9D279-5AE0-49B8-843C-D632284A6F65Q52689973-927CBA63-44D1-406F-87ED-6FEEA2C1F446Q55072103-3BF6153F-6BE0-4FFD-A547-A1E68C271FCEQ55106038-DEA623F1-69E6-427C-BACE-416579D20F61Q58765606-60FFF26B-79C2-4606-83F6-6BE21F5BA5F6
P2860
A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy
description
2015 nî lūn-bûn
@nan
2015 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy
@ast
A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy
@en
A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy
@nl
type
label
A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy
@ast
A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy
@en
A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy
@nl
prefLabel
A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy
@ast
A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy
@en
A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy
@nl
P2093
P2860
P3181
P1476
A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy
@en
P2093
Jonathan D. Powell
Robert D. Leone
Ying-Chun Lo
P2860
P304
P3181
P356
10.1016/J.CSBJ.2015.03.008
P407
P577
2015-04-08T00:00:00Z